Coloplast set new long-term goals
In the run up to last week’s capital market day, Coloplast’s board of directors has approved a new long-term financial guidance, spanning the next three to five years. The already solid EBIT-margin is set to expand.
by Leonora Beck
Since Coloplast’s CEO, Lars Rasmussen, took the reins in the Danish medtech group in 2008, he has lifted profitability significantly and increased the EBIT-margin from around 12% to 31.6%in the latest fiscal year. But the struggle to improve margins continues.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Coloplast’s Head of Media resigns
For abonnenter
”We keep an eye on them, same as always”
For abonnenter
Is Coloplast going for its rival’s spoils?
For abonnenter
